Expression of human CD59 in transgenic pig organs enhances organ survival in an ex vivo xenogeneic perfusion model.
The serious shortage of available donor organs for patients with end stage organ failure who are in need of solid organ transplantation has led to a heightened interest in xenotransplantation. The major barrier to successful discordant xenotransplantation is hyperacute rejection. Hyperacute rejection results from the deposition of preformed antibodies that activate complement on the luminal surface of the vascular endothelium, leading to vessel occlusion and graft failure within minutes to hours. Endogenous membrane-associated complement inhibitors normally protect endothelial cells from autologous complement -- however, these molecules are species-restricted and therefore are ineffective at inhibiting activated xenogeneic complement. To address the pathogenesis of hyperacute rejection in the pig-to-human combination, F1 offspring were generated from a transgenic founder animal that was engineered to express the human terminal complement inhibitor hCD59. High-level cell surface expression of hCD59 was detected in the hearts and kidneys of these transgenic F1 animals, similar to expression levels in human kidney tissue. The hCD59 was expressed on both large vessel and capillary endothelium. Ex vivo perfusion experiments, using human blood as the perfusate, were performed with transgenic porcine hearts and kidneys to evaluate the ability of hCD59 to inhibit hyperacute rejection. These experiments demonstrated that transgenic organs expressing hCD69 resisted hyperacute rejection, as measured by increased organ function for both the hearts and the kidneys, as compared with control pig organs. Hearts from hCD59-expressing animals demonstrated a five-fold prolongation in function compared with controls, 109.8 +/- 20.7 min versus 21.2 +/- 2.9 min (P = 0.164). The hCD59-expressing kidneys also demonstrated significantly prolonged function at 157.8 +/- 27.0 min compared with 60.0 +/- 6.1 min for controls (P = 0.0174). Deposition of C9 neoantigen In the vasculature of porcine organs perfused with human blood was markedly reduced in organs expressing hCD59. These studies demonstrate that C5b-9 plays an important role in hyperacute rejection of a porcine organ perfused with human blood and suggest that donor pigs transgenic for hCD59 may be an integral component of successful clinical xenotransplantation.
Kroshus
T J
TJ
Department of Surgery, University of Minnesota, Minneapolis, USA.
Bolman
R M
RM
Dalmasso
A P
AP
Rollins
S A
SA
Guilmette
E R
ER
Williams
B L
BL
Squinto
S P
SP
Fodor
W L
WL
D000818:Animals; D030801:Animals, Genetically Modified; D001483:Base Sequence; D018957:CD59 Antigens / Q000235:genetics* / Q000378:metabolism; D003167:Complement Activation; D003176:Complement C3 / Q000378:metabolism; D003186:Complement C9 / Q000378:metabolism; D017931:DNA Primers / Q000737:chemistry; D004195:Disease Models, Animal; D006084:Graft Rejection; D006321:Heart / Q000502:physiology; D006461:Hemolysis; D006801:Humans; D007668:Kidney / Q000502:physiology; D007963:Leukocytes, Mononuclear / Q000378:metabolism; D008969:Molecular Sequence Data; D010477:Perfusion; D014183:Transplantation, Heterologous / Q000379:methods*
D018957:CD59 Antigens; D003176:Complement C3; D003186:Complement C9; D017931:DNA Primers